OR2L9P

Across TCGA pan-cancer cohorts, OR2L9P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated OR2L9P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR2L9P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2L9P expression acts as an unfavorable survival marker.

STAD, MESO, and UVM are the cancer types where OR2L9P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.351	0.572	.001	81	view →
MESO	DFS	Tertile	III,IV	0.061	0.423	<.001	63	view →
UVM	DFS	Tertile	All	0.158	0.754	<.001	54	view →
PAAD	DFS	Tertile	All	0.068	0.468	<.001	54	view →
COAD	OS	Tertile	All	0.116	0.666	.027	36	view →
SARC	OS	Tertile	All	0.248	0.783	<.001	21	view →
GBM	DFS	Tertile	All	0.066	0.257	.019	18	view →
THCA	DFS	Tertile	IV	0.146	0.795	.004	18	view →
LUSC	OS	Tertile	II,III,IV	0.215	0.686	.020	18	view →
ESCA	DFS	Tertile	All	0.334	0.545	.040	9	view →
DLBC	DFS	Tertile	III,IV	0.067	0.712	.016	9	view →
SKCM	OS	Tertile	IV	0.226	0.613	.034	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

OR2L9P–STAD (DFS)

Open the STAD breakdown →